Tevogen Bio Launches AI Initiative with Microsoft and Databricks

Tevogen Bio Holdings Inc. has launched its artificial intelligence initiative, Tevogen.AI, in collaboration with Microsoft and Databricks, announced in a press release. This initiative aims to integrate advanced machine learning and predictive modeling into Tevogen's proprietary ExacTcell technology to enhance target identification and pre-clinical processes.

Tevogen.AI features two proprietary technologies, PredicTcell and AdapTcell, which are designed to improve precision in immunotherapy treatments and expand understanding of immune responses. PredicTcell focuses on predicting immunologically active peptide complexes, while AdapTcell decodes interactions between human leukocyte antigens and T cells.

The initiative is supported by strategic partnerships with Microsoft, which provides AI expertise and cloud computing infrastructure, and Databricks, which offers data engineering and analytics capabilities. These collaborations aim to accelerate drug discovery processes and refine AI models for better predictive accuracy.

Tevogen plans to expand its AI applications beyond its current scope, with dedicated facilities for its data scientists and engineers, as part of its growth strategy.